A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by Total Mesorectal Excision (TME) for treatment of locally advanced rectal cancer (LARC)

D Schrag;S Quian;M Weiser;M Gollub;L Saltz;G Chang;R Auer;J Farma;T George;V Gordon;B Musher;J Goldberg;T Kolevska;A Dueck;E Basch;A Venook;K Goodman;E O'Reilly;J Meyerhardt;H Mamon J Clin Oncol 41, 2023 (suppl 17; abstr LBA2); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), plenary session - oral

Preoperative Treatment of Locally Advanced Rectal Cancer

D Schrag;Q Shi;M Weiser;M Gollub;L Saltz;B Musher;J Goldberg;T Al Baghdadi;K Goodman;R McWilliams;J Farma;T George;H Kennecke;M Montemurro;G Nelson;B Colgrove;V Gordon;A Venook;E O'Reilly;J Meyerhardt;A Dueck;E Basch;G Chang;H Mamon N Engl J Med. Jul 27;389(4):322-334

PMid: PMID37272534 | PMC number: PMC10775881

Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the N1048 PROSPECT trial

E Basch;A Dueck;S Mitchell;H Mamon;M Weiser;L Saltz;M Gollub;L Rogak;B Ginos;G Mazza;B Colgrove;G Chang;L Minasian;A Denicoff;G Thanarajasingam;B Musher;T George;A Venook;J Farma;E O'Reilly;J Meyerhardt;Q Shi;D Schrag J Clin Oncol. Jul 20;41(21):3724-3734

PMid: PMID37270691 | PMC number: PMC10351948

Surgical Quality for Patients treated with Neoadjuvant Chemotherapy versus Chemoradiation for locally advanced rectal cancer (LARC): Results from PROSPECT (Alliance N1048)

M Weiser;Q Shi;G Chang;J Goldberg;R Auer;M Gollub;L Saltz;B Musher;T Al Baghdadi;J Farma;T George;B Colgrove;G Nelson;E O'Reilly;A Shargill;J Meyerhardt;H Mamon;D Schrag ESMO (October 20-24, 2023, Madrid, Spain), poster

Compliance and interim results of a cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE embedded in the Alliance N1048 PROSPECT rectal cancer clinical trial

A Dueck;S Mitchell;L Rogak;B Ginos;DJ Sargent;Q Shi;S Shrag;C Eng;C Crane;H Kennecke;A O'Mara;L Minasian;D Schrag;E Basch ISOQOL 2015 meeting (October 21-24, 2015, Vancouver, BC, CAN), oral presentation